tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Crinetics Pharmaceuticals: Promising Pipeline and Strategic Advancements Justify Buy Rating

Crinetics Pharmaceuticals: Promising Pipeline and Strategic Advancements Justify Buy Rating

In a report released on July 14, Joseph Schwartz from Leerink Partners reiterated a Buy rating on Crinetics Pharmaceuticals, with a price target of $80.00.

Elevate Your Investing Strategy:

Joseph Schwartz has given his Buy rating due to a combination of factors that highlight Crinetics Pharmaceuticals’ promising pipeline and strategic advancements. The company has demonstrated significant expertise in developing high-quality drug candidates, particularly in the field of orphan diseases. Their presence at the ENDO conference underscored their strong position in the industry, with a focus on their leading candidate, paltusotine, which is expected to transform the company into a commercial entity upon its anticipated approval.
In addition to paltusotine, Crinetics has a robust late-stage pipeline with ongoing Phase 3 trials for carcinoid syndrome and studies for atumelnant in various conditions. The emerging pipeline, including treatments for Graves’ disease, polycystic kidney disease, and obesity, further enhances the company’s potential for long-term growth. These developments suggest a promising future for Crinetics, justifying the Buy rating as they continue to de-risk their programs and generate value.

In another report released yesterday, Citizens JMP also reiterated a Buy rating on the stock with a $90.00 price target.

Disclaimer & DisclosureReport an Issue

1